Survival benefits with EPIC in addition to HIPEC for low grade appendiceal neoplasms with pseudomyxoma peritonei: a propensity score matched study

Abstract Objectives Appendiceal cancer is a rare malignancy, occurring in roughly 1.2 per 100,000 per year. Low grade appendiceal neoplasams (LAMN) in particular can lead to pseudomyxoma peritonei (PMP), and respond poorly to systemic chemotherapy. Standard treatment includes cytoreduction surgery (CRS) with addition of heated intraoperative peritoneal chemotherapy (HIPEC). Several centres include early postoperative intraperitoneal chemotherapy (EPIC) however; the literature is mixed on the benefits. We aim to examine the benefits of additional EPIC through a propensity-matched analysis. Methods Patients with LAMN with PMP who underwent cytoreductive surgery at St George hospital between 1996 and 2020 were included in this retrospective analysis. Propensity score matching was performed with the following used to identify matched controls; sex, age, American Society of Anesthesiologists (ASA) grade, peritoneal cancer index (PCI) and morbidity grade. Outcomes measured included length of stay and survival. Results A total of 224 patients were identified of which 52 received HIPEC alone. Propensity matching was performed to identify 52 matched patients who received HIPEC + EPIC. Those receiving HIPEC + EPIC were younger at 54.3 vs. 58.4 years (p=0.044). There was a median survival benefit of 34.3 months for HIPEC + EPIC (127.3 vs. 93.0 months, p=0.02). Median length of stay was higher in those who received EPIC (25.0 vs. 23.5 days, p=0.028). Conclusions In LAMN with PMP, the addition of EPIC to HIPEC with CRS improves overall survival in propensity score matched cases but results in prolonged hospitalisation. The use of EPIC should still be considered in selected patients.

• Publication year

  2023

• Venue

  Pleura and Peritoneum

• Publication date

  2023-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1515/pp-2022-0205PMID 37020474PMCID 10067551
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Early postoperative intraperitoneal chemotherapy (EPIC) following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in 632 patients with pseudomyxoma peritonei of appendiceal origin: A single institution experience.

  2022cited by this paper
• Peritoneal Spread of Low-grade Appendiceal Tumours – 2 Days of Early Postoperative Intra-peritoneal Chemotherapy Are Enough

  2021cited by this paper
• Continued increasing incidence of malignant appendiceal tumors in Canada and the United States: A population‐based study

  2020cited by this paper
• Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with or without early post-operative intraperitoneal chemotherapy for appendix neoplasms with peritoneal metastases: A propensity score analysis.

  2020cited by this paper
• Pleura and Peritoneum

  2019influential reference
• A Multicenter Randomized Trial to Evaluate Hematologic Toxicities after Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin or Mitomycin in Patients with Appendiceal Tumors.

  2018cited by this paper
• Early postoperative intraperitoneal chemotherapy is associated with survival benefit for appendiceal adenocarcinoma with peritoneal dissemination.

  2017cited by this paper
• A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process

  2016cited by this paper
• Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference?

  2016cited by this paper
• Early Postoperative Intraperitoneal Chemotherapy for Low-Grade Appendiceal Mucinous Neoplasms with Pseudomyxoma Peritonei: Is it Beneficial?

  2016cited by this paper
• Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase

  2015cited by this paper
• Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.

  2015cited by this paper
• Management of Appendix Cancer

  2015cited by this paper
• Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis secondary to mucinous adenocarcinoma of the appendix.

  2015cited by this paper
• Comparative analysis of perioperative intraperitoneal chemotherapy regimen in appendiceal and colorectal peritoneal carcinomatosis

  2013cited by this paper
• HIPEC + EPIC versus HIPEC‐alone: Differences in major complications following cytoreduction surgery for peritoneal malignancy

  2013cited by this paper
• Mucinous neoplasms of the appendix: a current comprehensive clinicopathologic and imaging review

  2013cited by this paper
• Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

  2012cited by this paper
• Early and long-term outcome data on 2,298 patients with pseudomyxoma peritonei of appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

  2012cited by this paper
• An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies

  2011cited by this paper
• Cancers of the Appendix: Review of the Literatures

  2011cited by this paper
• The Clavien-Dindo Classification of Surgical Complications: Five-Year Experience

  2009cited by this paper
• Pseudomyxoma Peritonei of Appendiceal Origin: A Clinicopathologic Analysis of 101 Patients Uniformly Treated at a Single Institution, With Literature Review

  2006cited by this paper
• Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.

  2004cited by this paper
• Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis.

  1996cited by this paper
• Peritonectomy procedures.

  1995cited by this paper
• Peritonectomy Procedures

  1995cited by this paper
• Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer.

  1989cited by this paper

• Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal mucocele tumors: Five case reports and review of literature

  2026cites this paper
• Executive Summary of the American Radium Society Appropriate Use Criteria for the Management of Peritoneal Carcinomatosis From Different Tumor Origins: Systematic Review and Guidelines

  2025influential citation
• Review Various facets of low-grade appendiceal mucinous neoplasms (LAMNs)

  year unknowncites this paper